{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperthyroidism/background-information/causes/","result":{"pageContext":{"chapter":{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes","depth":2,"htmlHeader":"<!-- begin field ea7b1440-1cd0-41b9-aed4-5d7778919407 --><h2>What are the causes?</h2><!-- end field ea7b1440-1cd0-41b9-aed4-5d7778919407 -->","summary":"","htmlStringContent":"<!-- begin item 697bacee-b99b-47c4-87d8-6d46ddece76d --><!-- begin field e492d3e5-2832-4ffd-9ae2-ff01af26964b --><p><strong>Causes of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/definition/\">thyrotoxicosis with hyperthyroidism</a> (increased thyroid hormone synthesis)</strong></p><ul><li><strong>Thyroidal origin</strong><ul><li><strong>Graves' disease</strong><ul><li>This is the most common cause of hyperthyroidism in iodine-sufficient areas, accounting for about 80% of cases. It is a systemic autoimmune disorder mediated by thyroid-stimulating hormone (TSH)-receptor antibodies (TRAbs) that stimulate the TSH receptor, leading to thyroid hyperplasia and unregulated excessive production and secretion of thyroid hormone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>].</li><li>Peak incidence is at 30–50 years of age, and it is 10 times more common in women than men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>Typical eye signs of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">Graves&#39; orbitopathy</a> occur in about one-third of cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2013</a>].</li><li>People with a personal or family history of autoimmune disorders, such as type 1 diabetes mellitus, are at increased risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>].</li></ul></li><li><strong>Toxic multinodular goitre</strong><ul><li>This is the second most common cause of hyperthyroidism in the UK, and is more common in older adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>It occurs in a thyroid gland with at least two autonomously functioning thyroid nodules that secrete excess thyroid hormone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Franklyn and Boelaert, 2012</a>]. Histologically the nodules are benign follicular adenomas [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>].</li><li>People over 60 years of age, and people living in iodine-deficient areas, such as Denmark, are at increased risk, as thyroid autonomy develops after a long period of low iodine intake [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li></ul></li><li><strong>Toxic thyroid nodule (adenoma)</strong><ul><li>This accounts for up to 5% of cases of hyperthyroidism, and is more common in older adults. The nodule produces enough hormone to suppress secretion of TSH from the pituitary, with consequent suppression of the contralateral thyroid lobe [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Franklyn and Boelaert, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>]. Histologically the nodule is a benign follicular adenoma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>].</li></ul></li><li><strong>TSH-secreting pituitary adenoma</strong><ul><li>This is a rare tumour secreting large quantities of TSH, leading to inappropriately normal or elevated TSH levels, with elevated free thyroxine (FT4), and total triiodothyronine (T3) levels. The pituitary does not respond to normal T4 and T3 feedback mechanisms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li><li><strong>Pituitary thyroid hormone resistance syndrome</strong><ul><li>This is a rare condition caused by genetic mutations in the thyroid hormone receptor-beta gene. A positive family history supports the diagnosis. Usually the person is euthyroid, but thyrotoxic symptoms may occur [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li><li><strong>High concentrations of human chorionic gonadotrophin (hCG)</strong><strong> </strong>can stimulate TSH receptors and suppress TSH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].<ul><li>Gestational thyrotoxicosis — this is a benign and transient disorder typically seen in the first trimester of pregnancy, caused by the stimulatory action of placental beta-hCG. There is an absence of thyroid autoimmunity, and it does not require any specialist treatment.</li><li>Hyperemesis gravidarum — defined as 5% weight loss of pre-pregnancy weight, dehydration, and ketonuria. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/\">Nausea/vomiting in pregnancy</a> for more information.</li><li>Chorionic gonadotrophin-secreting tumours, such as choriocarcinoma or hydatidiform mole (rare). Tumour produces beta-hCG, which stimulates thyroid TSH receptors.</li></ul></li><li><strong>Iodine</strong><ul><li>Iodine may suppress TSH levels and is found in over-the-counter preparations, such as kelp supplements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>Amiodarone-induced thyrotoxicosis (AIT type 1) — if a person with underlying thyroid disease is exposed to the high iodine content of amiodarone, this may lead to excess thyroid hormone synthesis and release [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>]. The long half-life of amiodarone may cause hyperthyroidism for up to one year after it is discontinued [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>].</li><li>Iodinated radiographic contrast agents may suppress TSH levels [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li></ul></li><li><strong>Extrathyroidal origin</strong><ul><li><strong>Struma ovarii</strong><ul><li>This describes ectopic thyroid hormone secretion from thyroid tissue located in an ovarian teratoma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li><li><strong>Functional thyroid cancer metastases</strong><ul><li>These can result in extrathyroidal foci of thyroid hormone production [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li></ul></li></ul></li></ul><p><strong>Causes of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/definition/\">thyrotoxicosis without hyperthyroidism</a> (increased availability of preformed thyroid hormone)</strong></p><ul><li><strong>Thyroidal origin</strong><ul><li><strong>Thyroiditis </strong>causes a usually transient release of pre-formed thyroid hormones into the circulation due to inflammatory destruction of the thyroid follicles, and includes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>]:<ul><li>Postpartum thyroiditis (PPT) — this is a painless, inflammatory autoimmune condition which typically occurs within 2–6 months after delivery or miscarriage. It is defined as the development of thyrotoxicosis, hypothyroidism, or thyrotoxicosis followed by hypothyroidism within a year of giving birth, in women who were euthyroid prior to pregnancy. Most women become euthyroid within 12 months of delivery, but there is a 30% risk of permanent hypothyroidism. If thyroid peroxidase autoantibodies (TPOAbs) are positive in early pregnancy, there is a 40–60% chance of PPT developing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li><li>Subacute (de Quervain's) thyroiditis — typically presents with thyroid pain and fever, and is thought to be due to a viral infection or a postviral inflammatory process [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li><li>Drug-induced — amiodarone-induced thyrotoxicosis (AIT type 2) describes a destructive thyroiditis caused by the direct toxic effect of amiodarone on thyroid cells (usually self-limiting); lithium rarely causes hyperthyroidism, and this may present more than one year after starting the drug; anti-retrovirals and cancer immunotherapy drugs such as interferon-alpha can precipitate thyroiditis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li></ul></li><li><strong>Extrathyroidal origin</strong><ul><li><strong>Exogenous thyroid hormone</strong><ul><li>Excess intake of levothyroxine (LT4) — in the UK, the most common cause of a serum TSH level less than 0.1 mU/L is excess use of LT4 medication which may be intentional (factitious) or unintentional (iatrogenic) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>]. Thyroid hormone may also be a constituent of over-the-counter weight loss supplements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information on prescribing and monitoring LT4 therapy.</li></ul></li></ul></li></ul><!-- end field e492d3e5-2832-4ffd-9ae2-ff01af26964b --><!-- end item 697bacee-b99b-47c4-87d8-6d46ddece76d -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","lastRevised":"Last revised in January 2021","chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","fullItemName":"Management","slug":"management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}